Abstract
GW5638 is a novel tissue-selective estrogen receptor (ER) modulator. Structurally, it is a derivative of tamoxifen that is known for its inhibitory effects on angiogenesis in an ER-independent manner. Therefore, it is possible that GW5638 has the same effects as tamoxifen on angiogenesis. To test this hypothesis, we used the rat cornea pocket assay and developed a new method that could precisely determine the total projected area of microvessels induced by basic fibroblast growth factor (bFGF) in the cornea. Animals in the study were treated with corn oil (control group), tamoxifen, or GW5638. After treatment, we observed that both GW5638 and tamoxifen could inhibit angiogenesis in the cornea (P<0.05) and that the inhibitory effects were not mediated by blocking functions of estrogen. Meanwhile, GW5638 had minimal effects on the body weight of animals whereas tamoxifen significantly reduced the body weight. Based on these observations, we concluded that GW5638 was as effective as tamoxifen in antiangiogenic treatment but less toxic than tamoxifen.
Abbreviations
- ER:
-
estrogen receptor
- bFGF:
-
basic fibroblast growth factor
- PBS:
-
phosphate buffered saline
References
Willson TM, Norris JD et al. (1997) Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology 138:3901–11
Howell A (2001) Future use of selective estrogen receptor modulators and aromatase inhibitors. Clin Cancer Res 7:4402s–10s
Bentrem D, Dardes R, Liu H et al. (2001) Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. Endocrinol 142:838–46
Connor CE, Norris JD, Broadwater G et al. (2001) Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. Cancer Res 61:2917–22
Gagliardi AR, Hennig B, Collins DC (1996) Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors. Anticancer Res 16:1101–6
Manolopoulos VG, Liekens S, Koolwijk P et al. Inhibition of angiogenesis by blockers of volume-regulated anion channels. Gen Pharmacol 2000; 34: 107–16
Kayyali R, Marriott C, Wiseman H (1994) Tamoxifen decreases drug efflux from liposomes: Relevance to its ability to reverse multidrug resistance in cancer cells? FEBS Lett 344:221–4
Custodio JB, Dinis TC, Almeida LM, Madeira VM (1994) Tamoxifen and hydroxytamoxifen as intramembraneous inhibitors of lipid peroxidation: Evidence for peroxyl radical scavenging activity. Biochem Pharmacol 47:1989–98
Clarke R, van den Berg HW, Murphy RF (1990) Reduction of the membrane fluidity of human breast cancer cells by tamoxifen and 17 beta-estradiol. J Natl Cancer Inst 82:1702–5
Wiseman H: (1994) Tamoxifen: New membrane-mediated mechanisms of action and therapeutic advances. Trends Pharmacol Sci 15:83–9
Wiseman H, Quinn P (1994) The antioxidant action of synthetic oestrogens involves decreased membrane fluidity: Relevance to their potential use as anticancer and cardioprotective agents compared to tamoxifen? Free Radic Res 21:187–94
Wiseman H, Smith C, Halliwell B et al. (1992) Droloxifene (3-hydroxytamoxifen) has membrane antioxidant ability: Potential relevance to its mechanism of therapeutic action in breast cancer. Cancer Lett 66:61–8
Wiseman H (1994) Tamoxifen: Molecular Basis of Use in Cancer Treatment and Prevention. John Wiley & Sons, New York
Degani H, Furman E, Fields S (1994) Magnetic resonance imaging and spectroscopy of MCF7 human breast cancer: Pathophysiology and monitoring of treatment. Clin Chim Acta 228:19–33
Furman-Haran E, Margalit R, Maretzek AF, Degani H (1996) Angiogenic response of MCF7 human breast cancer to hormonal treatment: Assessment by dynamic GdDTPA-enhanced MRI at high spatial resolution. J Magn Reson Imaging 6:195–202
Gagliardi A, Collins DC (1993) Inhibition of angiogenesis by antiestrogens. Cancer Res 53:533–5
Haran EF, Maretzek AF, Goldberg I et al. (1994) Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. Cancer Res 54:5511–4
Kelloff GJ, Boone CW, Steele VE et al. (1994) Mechanistic considerations in chemopreventive drug development. J Cell Biochem Suppl 20:1–24
Lindner DJ, Borden EC (1997) Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis. Int J Cancer 71:456–61
McLeskey SW, Zhang L, Trock BJ et al. (1996) Effects of AGM-1470 and pentosan polysulphate on tumorigenicity and metastasis of FGF-transfected MCF-7 cells. Br J Cancer 73:1053–62
Oehler MK, Hague S, Rees MC, Bicknell R (2002) Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis. Oncogene 21:2815–21.
Thamrongwittawatpong L, Sirivatanauksorn Y, Batten JJ et al. (2001) The effect of N(G)-monomethyl-L-arginine and tamoxifen on nitric oxide production in breast cancer cells stimulated by oestrogen and progesterone. Euro J Surg 167:484–9
Zhang HT, Craft P, Scott PA et al. (1995) Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 87:213–9
Asahara T, Chen D, Takahashi T et al. (1998) Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 83:233–40
Ausprunk DH, Folkman J (1977) Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14:53–65
Ausprunk DH, Falterman K, Folkman J (1978) The sequence of events in the regression of corneal capillaries. Lab Invest 38:284–94
Fournier GA, Lutty GA, Watt S et al. (1981) A corneal micropocket assay for angiogenesis in the rat eye. Invest Ophthalmol Vis Sci 21:351–4
Gimbrone MAJ, Cotran RS, Leapman SB, Folkman J (1974) Tumor growth and neovascularization: An experimental model using the rabbit cornea. J Natl Cancer Inst 52: 413–27
Kenyon BM, Voest EE, Chen CC et al. (1996) A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 37:1625–32
Muthukkaruppan V, Auerbach R (1979) Angiogenesis in the mouse cornea. Science 205:1416–8
Polverini PJ, Bouck NP, Rastinejad F (1991) Assay and purification of naturally occurring inhibitor of angiogenesis. Methods Enzymol 198:440–50
Benelli U, Ross JR, Nardi M, Klintworth GK (1997) Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A. Invest Ophthalmol Vis Sci 38:274–82
Jain RK, Schlenger K, Höckel M, Yuan F (1997) Quantitative angiogenesis assays: Progress and problems. Nat Med 3:1203–8
Li WW, Grayson G, Folkman J, D’Amore PA (1991) Sustained-release endotoxin. A model for inducing corneal neovascularization. Invest Ophthalmol Vis Sci 32:2906–11
Conrad TJ, Chandler DB, Corless JM, Klintworth GK (1994) In vivo measurement of corneal angiogenesis with video data acquisition and computerized image analysis. Lab Invest 70:426–34
Auerbach R, Arensman R, Kubai L, Folkman J (1975) Tumor-induced angiogenesis: Lack of inhibition by irradiation. Int J Cancer 15:241–5
Sierra-Honigmann MR, Nath AK, Murakami C et al. (1998) Biological action of leptin as an angiogenic factor. Science 281:1683–6
Proia AD, Chandler DB, Haynes WL et al. (1988) Quantitation of corneal neovascularization using computerized image analysis. Lab Invest 58:473–9
Blackwell KL, Haroon ZA, Shan S et al. (2000) Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin Cancer Res 6:4359–64
Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Sem Oncol 29(6 Suppl 16):15–8
Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727–39
Thackray BD, Nelson AC (1993) Semi-automatic segmentation of vascular network images using a rotating structuring element (ROSE) with mathematical morphology and dual feature thresholding. IEEE Trans Med Imaging 12:385–92
Sheng T, Yuan F (2001) Numerical simulations of angiogenesis in the cornea. Microvasc Res 61:14–27
Lesclous P, Guez D, Llorens A, Saffar JL (2001) Time-course of mast cell accumulation in rat bone marrow after ovariectomy. Calcif Tissue Int 68:297–303
Acknowledgments
The authors would like to thank Dr. Donald P.␣McDonnell for scientific discussion. The work supported in part by a grant from the Department of Defense (BC980191).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tong, S., Chen, Q., Shan, SQ. et al. Quantitative comparison of the inhibitory effects of GW5638 and tamoxifen on angiogenesis in the cornea pocket assay. Angiogenesis 9, 53–58 (2006). https://doi.org/10.1007/s10456-006-9029-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10456-006-9029-x